IFP Advisors Inc increased its stake in Henry Schein, Inc. (NASDAQ:HSIC – Get Rating) by 8.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,698 shares of the company’s stock after buying an additional 217 shares during the quarter. IFP Advisors Inc’s holdings in Henry Schein were worth $389,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. raised its position in Henry Schein by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 15,331,533 shares of the company’s stock worth $1,336,756,000 after purchasing an additional 214,846 shares during the period. Macquarie Group Ltd. increased its stake in Henry Schein by 7.9% in the third quarter. Macquarie Group Ltd. now owns 2,434,865 shares of the company’s stock worth $159,915,000 after purchasing an additional 178,783 shares during the period. Fiduciary Management Inc. WI lifted its position in shares of Henry Schein by 45.5% during the third quarter. Fiduciary Management Inc. WI now owns 1,913,031 shares of the company’s stock worth $125,820,000 after purchasing an additional 597,877 shares during the last quarter. Burgundy Asset Management Ltd. boosted its stake in shares of Henry Schein by 4.6% during the third quarter. Burgundy Asset Management Ltd. now owns 1,735,205 shares of the company’s stock valued at $114,124,000 after purchasing an additional 76,812 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Henry Schein by 3.2% in the third quarter. Dimensional Fund Advisors LP now owns 1,350,404 shares of the company’s stock worth $88,827,000 after purchasing an additional 41,240 shares during the last quarter. Institutional investors own 95.45% of the company’s stock.
Analyst Ratings Changes
HSIC has been the subject of several research reports. Morgan Stanley lowered their price objective on shares of Henry Schein from $70.00 to $69.00 and set an “underweight” rating for the company in a research report on Tuesday, February 21st. StockNews.com upgraded Henry Schein from a “hold” rating to a “buy” rating in a report on Saturday, April 8th. Credit Suisse Group lowered their target price on Henry Schein from $99.00 to $97.00 and set an “outperform” rating for the company in a report on Tuesday, February 28th. UBS Group raised their price target on Henry Schein from $75.00 to $82.00 and gave the company a “neutral” rating in a research note on Tuesday, March 7th. Finally, Piper Sandler upped their price objective on shares of Henry Schein from $85.00 to $97.00 and gave the stock an “overweight” rating in a research note on Monday, February 6th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $85.89.
Insider Buying and Selling at Henry Schein
Henry Schein Stock Up 0.1 %
Henry Schein stock opened at $79.80 on Tuesday. The business has a fifty day moving average price of $80.57 and a 200-day moving average price of $80.41. Henry Schein, Inc. has a 1-year low of $64.75 and a 1-year high of $89.72. The stock has a market capitalization of $10.47 billion, a price-to-earnings ratio of 20.51, a PEG ratio of 1.84 and a beta of 0.82. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.79 and a quick ratio of 0.91.
Henry Schein (NASDAQ:HSIC – Get Rating) last issued its quarterly earnings results on Thursday, February 16th. The company reported $1.35 earnings per share for the quarter, topping analysts’ consensus estimates of $1.21 by $0.14. The business had revenue of $3.37 billion for the quarter, compared to analyst estimates of $3.37 billion. Henry Schein had a return on equity of 15.79% and a net margin of 4.25%. The company’s revenue was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.07 earnings per share. Equities research analysts forecast that Henry Schein, Inc. will post 5.32 EPS for the current fiscal year.
Henry Schein Profile
Henry Schein, Inc engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgical, diagnostic tests, infection-control products, and vitamins.
Featured Articles
- Get a free copy of the StockNews.com research report on Henry Schein (HSIC)
- Is the Electric Vehicle Movement Losing Steam?
- 3 High-Yield Banks Insiders Are BuyingÂ
- Will ChatGPT Be the Final Nail in the Coffin for Chegg?
- Is the Market Reacting Too Negatively to Pinterest Earnings?
- More Analysts Should See Energizer Holdings As A Buy: Here Is Why
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC – Get Rating).
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
